Cynata Therapeutics Valuation

Is 51S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 51S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 51S's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 51S's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 51S?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 51S. This is calculated by dividing 51S's market cap by their current preferred multiple.
What is 51S's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	AU$48.78m

51S key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	18.4x
Enterprise Value/EBITDA	-4.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 51S's PS Ratio compare to its peers?

The above table shows the PS ratio for 51S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.1x
MDG1 Medigene	4.2x	16.1%	€31.0m
HPHA Heidelberg Pharma	11.8x	12.3%	€112.8m
CNW co.don	0.7x	n/a	€6.5m
2INV 2invest	7.8x	n/a	€60.4m
51S Cynata Therapeutics	21.1x	70.4%	€48.8m

Price-To-Sales vs Peers: 51S is expensive based on its Price-To-Sales Ratio (21.1x) compared to the peer average (7.9x).

Price to Earnings Ratio vs Industry

How does 51S's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	34.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	34.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 51S is expensive based on its Price-To-Sales Ratio (21.1x) compared to the European Biotechs industry average (8.6x).

Price to Sales Ratio vs Fair Ratio

What is 51S's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

51S PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	21.1x
Fair PS Ratio	16.3x

Price-To-Sales vs Fair Ratio: 51S is expensive based on its Price-To-Sales Ratio (21.1x) compared to the estimated Fair Price-To-Sales Ratio (16.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.